Therapy News and Research

RSS

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

Study opens new avenues of research to improve care for patients with COPD

Researchers from Boston University School of Medicine have pinpointed a genetic signature for chronic obstructive pulmonary disease from airway cells harvested utilizing a minimally invasive procedure.

12 Apr 2013

Gabriel Hortobagyi recognized with AACR-MICR Jane Cooke Wright Lectureship

Gabriel Hortobagyi, M.D., professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, will receive the Jane Cooke Wright Lectureship from the American Association for Cancer Research and its Minorities in Cancer Research membership group.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

Alzheimer's Association lauds Obama Administration for dedicating additional $100M to fight Alzheimer's

The Alzheimer's Association commends the Obama Administration for dedicating an additional $100 million within the President's FY 2014 budget toward the fight against Alzheimer's and the implementation of the National Plan to Address Alzheimer's Disease.

12 Apr 2013

New initiative launched to create more effective ED therapies based on brain imaging studies

Current treatments for anorexia and bulimia nervosa, which afflict an estimated 10 to 24 million Americans, are often limited and ineffective.

12 Apr 2013

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.

11 Apr 2013

CPAP treatment increases work productivity for people with sleep apnoea

Continuous positive airway pressure is effective at increasing work productivity, according to a new study.

11 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome. This new therapy proposes the modulation of the cerebral endocannabinoid system in order to ameliorate the symptoms of the disease.

11 Apr 2013

Gold nano-bullets to defeat cancer

Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Scientists at The Scripps Research Institute have shed light on one of the major toxic mechanisms of Alzheimer's disease. The discoveries could lead to a much better understanding of the Alzheimer's process and how to prevent it.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

UTHealth study explores ways to reduce infant exposure to secondhand smoke

A study to investigate whether a hospital-initiated behavioral therapy program conducted in the neonatal intensive care unit can reduce secondhand smoke in homes with infants at risk for pulmonary problems has been launched by researchers at The University of Texas Health Science Center at Houston.

11 Apr 2013

Computational simulations can help understand, treat cardiac rhythm disorders

Computational models of the human heart can be very useful in studying not just the basic mechanisms of heart function, but also to analyze the heart in a diseased state, and come up with methods for diagnosis and therapy.

11 Apr 2013

South Africa announces rollout of new single-dose ARV therapy

"South Africa's Health Minister Aaron Motsoaledi announced on Monday the launch of a new single-dose combination antiretroviral drug that will cost just 89 rand a month ($10) per patient, potentially revolutionizing AIDS treatment in the country," Salon reports (McDonough, 4/9).

11 Apr 2013

Reduction in neurogenesis associated with loss of certain cognitive faculties

These results incentivise the development of targeted therapies enabling improved neurone production to alleviate cognitive decline in the elderly and reduce the cerebral lesions caused by radiotherapy.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

Therapy News and Research

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Study opens new avenues of research to improve care for patients with COPD

Gabriel Hortobagyi recognized with AACR-MICR Jane Cooke Wright Lectureship

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

Alzheimer's Association lauds Obama Administration for dedicating additional $100M to fight Alzheimer's

New initiative launched to create more effective ED therapies based on brain imaging studies

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

CPAP treatment increases work productivity for people with sleep apnoea

Androgen receptors found to be a potential target in breast cancer

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Gold nano-bullets to defeat cancer

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

UTHealth study explores ways to reduce infant exposure to secondhand smoke

Computational simulations can help understand, treat cardiac rhythm disorders

South Africa announces rollout of new single-dose ARV therapy

Reduction in neurogenesis associated with loss of certain cognitive faculties

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News